Full Press Release Details
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program.
IDYA
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program
Key Takeaway: IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ 11 Tumors and Preclinical MAT2A Synthetic Lethality Program